Table 2.
Variables | AD-naïve | Overall | NMD | MD | BD |
---|---|---|---|---|---|
|
|
|
|
|
|
n = 80 | n = 71 | n = 35 | n = 17 | n = 19 | |
Age (years) | 59 (47–65) | 53 (43–53) | 53 (45–57) | 56 (52–63) | 47 (45–55) |
Gender (n, %) | |||||
Female | 42 | 40 | 19 | 10 | 11 |
Male | 38 | 31 | 16 | 7 | 8 |
Education (years) | 14 (12–26) | 14 (12–26) | 14 (12–26) | 14 (12–26) | 12 (12–26) |
Total treated drugs (n) | |||||
ADs | 0 | 122 | 71 | 25 | 26 |
SSRI | 0 | 35 | 21 | 7 | 7 |
SNRI | 0 | 27 | 13 | 7 | 7 |
NaSSA | 0 | 32 | 22 | 5 | 5 |
TCA | 0 | 9 | 4 | 3 | 2 |
Others | 0 | 18 | 12 | 3 | 3 |
Mood stabilizer | 0 | 27 | 10 | 6 | 11 |
Antipsychotics | 0 | 22 | 8 | 3 | 11 |
Benzodiazepines | 34 | 79 | 36 | 24 | 19 |
Dose of ADs (mg/day) imipramine equivalents | 0 | 150 (125–175) | 150 (125–175) | 150 (125–175) | 125 (100–150)* |
Median number of treated agents per one patient | |||||
ADs | 0 | 2 (1–2) | 2 (1–2) | 1 (1–2)** | 1 (1–2)** |
Mood stabilizer | 0 | 0 (0–1) | 0 (0–1) | 0 (0–1) | 1 (0–1) |
Antipsychotics | 0 | 0 (0–1) | 0 (0–1) | 0 (0–1) | 1 (0–1)* |
Benzodiazepines | 0 (0–1) | 1 (1–1) | 1 (1–1) | 1 (1–2) | 1 (1–1) |
Period from hospitalization to direction by pharmacist (days) | 15 (11–21) | 17 (11–21) | 14 (12–19) | 16 (12–21) | |
Number of conducted PAIs (n) | 4 (1–5) | 4 (1–5) | 4 (2–5) | 4 (2–5) |
Notes: Values are presented as median [quartile 1 to quartile 3];
P < 0.017,
P < 0.003 versus patients with nonmelancholic depression (compared using the Kruskal–Wallis test followed by the Mann–Whitney test, and analyzed for statistical differences using Bonferroni’s correction).
Abbreviations: Overall, overall antidepressant-treated patients; MD, melancholic depression; NMD, nonmelancholic depression; BD, bipolar depression; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin noradrenaline reuptake inhibitor; NaSSA, noradrenergic and specific serotonergic antidepressant; TCA, tricyclic antidepressants; AD, antidepressants.